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Opsomming 
 
Agtergrond: Morfien aktiveer kutane mastselle direk op 'n oënskynlik dosis-afhanklike wyse, 
wat lei tot die vrystelling van beide histamien en tryptase in die bloedstroom. Tryptase word 
feitlik uitsluitlik gestoor in mastselle. Verhoogde serum tryptase konsentrasie dien as 'n 
aanduiding van mastsel aktivering en het die mees gebruikte laboratorium ondersoek in 
anafilakse geword. Na 'n kliniese diagnostiese dilemma, is ons studie daarop gemik om die vraag 
te beantwoord of mastsel tryptase konsentrasie steeds nuttig is in die diagnose van anafilakse 
selfs na toediening van hoë dosis morfien. 
 
Metodes: Ons het 'n nie-geblinde, gerandomiseerde studie gedoen om die effek van fentaniel 
en hoë dosis morfien op serum massel tryptase konsentrasies te vergelyk. 'n Krag analise is 
uitgevoer. Twintig volwassenes wat hartchirurgie sou ondergaan is ewekansig toegewys aan 
een van twee opioïed regimens. Beide groepe het 'n fentaniel bolus van tussen 3 en 8 mkg/kg 
met induksie ontvang. In die fentaniel groep is dit gevolg deur 'n fentaniel infusie van 5 tot 10 
mkg/kg/uur tot die einde van chirurgie. Pasiënte in die morfien groep het morfien 1 mg / kg oor 
dertig minute ontvang. Serum mastsel tryptase konsentrasies is bepaal direk voor induksie van 
narkose en weer 90 minute na die aanvang van die opioïed infusie. Die primêre eindpunt was 
statistiese verskille in tryptase konsentrasie tussen die morfien en fentaniel groepe by die twee 
tydpunte. 
 
Resultate: Tien pasiënte met soortgelyke demografie is ingeskryf in elke groep. In die fentaniel 
groep was die tweede, 90 minute mastsel tryptase konsentrasie statisties beduidend (10.1%) 
laer (P = 0,006) as basislyn. Ten spyte daarvan dat die 95% -vertrouensintervalle van die verskil 
tussen die gemiddelde (-1,06 tot -0,34 mkg/L) nie nul insluit nie, sluit dit nie ‘n klinies belangrike 
verskil in nie. In die morfien groep het serum mastsel tryptase konsentrasies in die tweede (90 
minute) monster nie statisties betekenisvol verskil van die basislyn waardes nie, en sluit die 95% 
-vertrouensintervalle nul in. Geen tussen-groep verskille in tryptase konsentrasie is opgespoor 
nie. Een pasiënt in die morfien groep het 'n klinies beduidende toename van 50,4% in tryptase 
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konsentrasies gehad, hoewel vanaf 'n hoë basislyn van 11,9 mkg/L. In hierdie klein studie is dit 'n 
voorkoms van 10% (95% CI 1.8% tot 40.4.) 
 
Gevolgtrekking: In hierdie loodsstudie is serum mastsel tryptase konsentrasies nie beinvloed 
deur of fentaniel of hoë dosis morfien toediening nie. Die nul-hipotese, dat daar geen 
beduidende toename in serum mastsel konsentrasie na hoë dosis morfien in vergelyking met 
fentaniel tydens kardiale narkose en chirurgie is nie, is dus aanvaar. Groter studies word egter 
benodig om 'n seker gevolgtrekking te kan maak, veral in die morfien groep. 
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Summary 
 
Background: Morphine directly activates cutaneous mast cells in a seemingly dose-dependent 
manner, resulting in the release of both histamine and tryptase into the bloodstream. Tryptase 
is almost exclusively stored in mast cells. Elevated serum tryptase concentrations serve as an 
indicator of mast cell activation and have become the most frequently used laboratory 
investigation in anaphylaxis. Following a clinical diagnostic dilemma our study was aimed at 
answering whether mast cell tryptase concentration remains useful in supporting the diagnosis 
of anaphylaxis even after administration of high dose morphine.  
Methods:  We conducted a non-blinded, randomized controlled trial comparing the effects of 
fentanyl and high dose morphine, on serum mast cell tryptase concentrations. A power analysis 
was performed. Twenty adults undergoing cardiac surgery were randomly assigned to one of 
two opioid regimens. Both groups received a fentanyl bolus of 3 to 8 mcg/kg at induction. In the 
fentanyl group this was followed by a fentanyl infusion of 5 to 10 mcg/kg/hr until completion of 
surgery. Patients in the morphine group received morphine 1 mg/kg infused over thirty minutes. 
Baseline serum mast cell tryptase concentrations were determined directly prior to induction of 
anaesthesia and again 90 minutes after the start of the opioid infusion. The primary endpoint 
was statistical differences in tryptase concentrations between the morphine and fentanyl 
groups at the two time periods.  
 
 
Results: Ten patients of similar demographics were enrolled in each group. In the fentanyl group 
the second, 90-minute mast cell tryptase concentration was statistically significantly (10.1%) 
lower (p = 0.006) than baseline. Despite the 95% confidence interval of the difference between 
the means (-1.06  to -0.34 mcg/L) not including zero , this was not a clinically important 
difference. 
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In the morphine group serum mast cell tryptase concentrations in the second (90 minute) 
sample were not statistically different from baseline values, the 95% confidence interval 
including zero. No between-group differences in tryptase concentration were detected.  One 
patient in the morphine group exhibited a clinically significant 50,4% increase in tryptase 
concentrations, albeit from a high baseline of 11.9 mcg/L, which in this small study constitutes a 
prevalence of 10% (95% CI 1.8% to 40.4.) 
Conclusion: In this small pilot study, serum mast cell tryptase concentrations were unaffected 
by whether fentanyl or high dose morphine was administered. The null hypothesis, that there is 
no significant increase in serum mast cell concentrations after high dose morphine compared to 
fentanyl during cardiac anaesthesia and surgery, was therefore accepted. Larger studies are 
however needed to ensure a robust result, especially in the morphine group. 
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Detailed literature review 
 
Mast cell physiology  
Introduction 
Mast cells were first described by Paul Ehrlich during the 18th century.[1,2] They are immune 
cells that play a crucial role in the initiation of allergic diseases and type 1-hypersensitivity 
reactions like anaphylaxis.[3,4] Other functions are varied and may include involvement in 
inherent and adaptive immunity,[2] some autoimmune diseases,[5] tissue repair[4] as well as 
protection from certain bacterial and parasitic infections.[1,6] 
 
 
Mast cell morphology 
Mast cells are normally oval to stretched-out in shape with a single non-segmented nucleus.[7] 
The cytoplasm of mast cells is tightly packed with granules containing histamine, proteases 
(enzymes which break down proteins and peptides) and proteoglycans like heparin.[8] The 
surface of mast cells contain high affinity immunoglobulin E (Fc epsilon) receptors, low-affinity 
immunoglobulin G receptors, assorted G-protein coupled receptors, Toll-like receptors,[9] as 
well as receptors for stem cell factor.[2,7,10] 
 
 
Mast cell development 
Mast cells stem from CD34+ multipotent hematopoietic cells present in bone marrow.[2,4,11] 
Unlike basophils, mast cells are released into the circulation as immature cells and only undergo 
maturation and further development when they reach their specific target tissues.[2,3,12] 
Although found scattered throughout skin and mucosa, they are especially plentiful in areas 
close to blood vessels and in surfaces that lie close to the outside environment.[13] 
veien 
Mast cell classification  
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Mast cells are categorized into different subtypes according to the kind of protease enzymes 
stored in their cytoplasmic organelles[8,11] and consist of:   
1. Mast cells containing tryptase stored in their granules: this type is most predominant in 
lung tissue,[11] 
2. Mast cells containing chymase and tryptase: this type is concentrated in skin,[11,13] and 
3. Mast cells containing only chymase without tryptase in their granules. [11] 
 
Mast cell heterogeneity 
An important concept in mast cell biology is that mast cells  “do not represent a homogenous 
population”.[2] Not only do they store different biologically active substances in their 
cytoplasmic organelles as outlined above, they also differ with regard to: 
1. The locations and conditions in which they mature (their “microenvironments”),[2] and 
2. Their vulnerability to activation and subsequent response to stimulation.[4,6] 
 
Just as mast cells in different locations display distinct characteristics, similarly mast cells found 
in the same areas or tissues may be significantly different from each other.[2] 
 
Mast cell activation mechanisms 
The activation mechanism of mast cell can be considered to be mediated through either: 
1.  Binding at the high-affinity immunoglobulin E receptor (FcεRI), and/or 
2.  Mechanisms that do not involve the immunoglobulin E receptor.[2] 
 
The most frequent mechanism of mast cell activation is via antigen binding to the FcεRI 
receptor.[14] Mast cell activation involves degranulation followed by synthesis of new 
mediators, predominantly chemokines, cytokines, and arachadonic acid metabolites. The 
signalling pathways initiating eicosanoid and cytokine production are not well understood and 
appear to be distinct from those involved in degranulation.[15] 
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The process of IgE mediated degranulation occurs is relatively well understood. Previous contact 
with a foreign antigen results in the production of specific IgE antibodies. These antibodies 
become bound to IgE receptors on mast cells.[11] When the same antigen is again introduced it 
binds to immunoglobulin molecules on the mast cell surface (“cross-linking of the Fc-bound 
IgE”).[2] These bound receptors come together in specialized areas on the mast cell membrane 
to initiate the activation of mast cells.[15] The exact mechanism involved in the intracellular 
signalling processes that follow after the convergence of receptors are still not completely 
understood.[2,15] Two second-messenger systems involved in the signalling process are inositol 
trisphosphate (IP3) and diacylglycerol (DAG). Receptor binding activates the enzyme 
phospholipase C gamma, an isoform of phospholipase C; this ultimately culminates in the 
production of IP3 and DAG.[15] IP3 releases calcium stored in the endoplasmic reticulum and 
DAG activates the enzyme protein kinase C. These two events act together to trigger 
exocytosis.[2,15] 
 
 Mast cells can be activated by a variety of mechanism that do not involve the high-affinity 
immunoglobulin E receptor, the most important of these being: 
1. Complement (Anaphylatoxins): C3a and C5a activate specific receptors for complement 
fragments,[11]  
2. Bridging of Immunoglobulin G  (IgG) Receptors,[2,7] 
3. Stem cell factor through its receptor c-KIT,[15] 
4. Neuropeptides and cytokines like substance P, vasoactive intestinal peptide along with 
some interleukins,[2] 
5. Activation of Toll-like receptors on the mast cell surface (i.e. through the action of 
bacterial products),[9] 
6. Toxins like snake and wasp venom,[10] 
7. Drugs including contrast media, curare and opioids like morphine[16] and pethidine, 
and/or  
8. Morphine that appears to degranulate mast cells via a mechanism that involves neither 
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immunoglobulin receptors nor opioid receptors is discussed later. 
 
Mast cell mediator production 
Following mast cell activation, secretion of granular content may occur in various ways, these 
being anaphylactic degranulation, piecemeal degranulation, or degranulation-independent 
chemokine secretion. 
 
Anaphylactic degranulation follows IgE mediated mast cell activation and is the best know 
mechanism of mast cell mediator release. Following activation, stored mediators are released 
rapidly and completely via exocytosis to mediate immediate hypersensitivity reactions. In this 
process the membranes of the secretory granules fuse with each other as well as the plasma 
membrane to expel granular content into the extra-cellular environment.[17-19] 
 
 
In contrast to anaphylactic degranulation, piecemeal degranulation is a slower process of 
secretion whereby certain mediators can be released ‘selectively’ without degranulation taking 
place. It has been identified as a mechanism of mast cell secretion during many inflammatory 
diseases such as urticarial pigmentosa, bullous pemphigoid and ulcerative colitis. During 
piecemeal degranulation the mast cell granules slowly lose their content. Ultra-structural 
characteristics of piecemeal degranulation include a combination of the following features 
within the same cell: 
1. Normal mast cell granules, 
2. Empty granules, and/ or  
3. Altered granules.   
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It has been suggested that mast cell granules empty and fill through the action of small vesicles 
in the cytoplasm, the so-called “Vesicular shuttling hypothesis”. The triggers of selective release 
is not as well know as those causing anaphylactic degranulation.[17,19,20] Selective release has 
been demonstrated for substances such as eicosanoids[21] and serotonin.[22] 
 
Degranulation-independent chemokine secretion is another form of mast cell activation. Fischer 
et al. showed that mast cells could be selectively activated to synthesize chemokine’s without 
the release of pre-formed mediators via degranulation or the production of leukotriene’s.[20] 
 
Mast cell mediators and their functions 
Mast cell activation, regardless of the underlying mechanism, results in a diverse collection of 
biologically active substances both secreted and subsequently produced by activated mast cells. 
These can be divided as follows: 
1. Immediate release of pre-formed granular mediators: There are substances stored and 
“pre-packaged” in cytoplasmic granules, ready for rapid release during mast cell 
degranulation, 
2. Synthesis of membrane lipid mediators, eicosanoids, occurs within minutes and 
3. The synthesis of cytokines and chemokine’s is delayed by minutes to hours.[7,23,24] 
 
Pre-formed mediators within the cytoplasmic granules of mast cells contain mainly histamine, 
heparin and proteases. Proteases present in mast cells include tryptase, chymase and 
carboxypeptidase, tryptase being the most frequently measured of the three.[11,25] In addition, 
these organelles also store proteoglycans like heparin. It appears that their function is to bind to 
and stabilize, other substances in the granules.[7] 
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Histamine is derived from histidine (an amino acid) and is present in both mast cells as well as 
basophils.[25] The effects are mediated through G-protein coupled receptors, delineated H1 to 
H4. Stimulation by histamine results in: 
1. Vasodilatation and increased vascular permeability via the production of nitric oxide and 
activation of potassium channels in vascular endothelium, 
2. Increased cardiac inotropy and chronotropy and ultimately increased cardiac output, 
3. Urticaria and angioedema, 
4. Bronchospasm and coronary artery spasm from contraction of smooth muscle, 
5. Abdominal pain from contraction of smooth muscle and 
6. Increased viscosity of mucous and increased glandular secretions.[2,7,10,25] 
 
Mast cell tryptases are enzymes with trypsin-like characteristics.[5] Together with chymases 
they are the major proteins in mast cell granules.[10]  The major tryptase subtypes are 
membrane-bound gamma tryptase and soluble tryptases. The latter are divided into alpha, beta 
and delta gamma tryptases,[7] with Beta-tryptases divided in to beta 1,2,3 and alpha-tryptases 
are divided into alpha 1 and 2 subgroups.                  [10,11] Beta tryptase is composed of four 
subunits (creating a tetramer); each subunit containing one active enzyme site.[26] All the active 
enzyme sites of the tryptase tetramer face inward towards a central opening. This configuration 
protects the compound from enzymatic breakdown as protease inhibitors have difficulty 
accessing their binding sites.[26] Neither the biological role of mast cell tryptase nor its 
regulation in vivo is completely understood.[26]  However the functions of mast cell tryptase are 
thought to comprise:      
1. Stimulation of growth and development of certain cells,[11] 
2. Attraction of immune cells to areas of inflammation,[3] and 
3. Activation of nearby mast cells in an “autocrine action”. [3]  
 
Tryptases exerts their effects through G-protein coupled receptors known as protease activated 
receptors (PAR’s) that are found in, amongst other places, the respiratory tract and the vascular 
system.[11] 
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Eicosanoid lipid mediators are synthesised after degranulation occurs. These eicosanoids are 
produced from twenty-carbon essential fatty acids, usually cell membrane arachidonic acid. This 
process that requires the enzyme phospholipase A2.[24,27] The ultimate end products, 
leukotrienes and prostaglandins, are then produced through the cyclooxygenase and 5-
lipoxygenase pathways respectively.[7,25] 
 
Prostaglandin D2 is the chief prostaglandin produced by mast cells. It acts on prostaglandin 
receptors present in most tissues to mediate effects such as: 
1. Peripheral vasodilatation, 
2. Coronary and pulmonary artery constriction, and 
3. Bronchospasm.[25] 
 
Prostaglandin F2 Alpha, Prostaglandin E2 and thromboxane A2 are also synthesized, all of which 
can cause bronchoconstriction and vasodilatation.[25] 
 
Leukotrienes also act through G-Protein coupled receptors to induce: 
1. Bronchoconstriction, 
2. Increase vascular permeability, and/or 
3. Mucous production.[7] 
 
Platelet activating factor is a leukotrine which stimulates platelet aggregation, 
bronchoconstriction and increases vascular permeability.[25] 
 
Chemokine and cytokine production represents the final consequence of mast cell activation 
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is the synthesis of various chemokines and cytokines. The production of cytokines and 
chemokines gives rise to the biphasic phase of anaphylactic reactions.[24] Tumour necrosis 
factor-alpha is the major cytokine released. TNF-alpha together with interleukins 1 to 6 are 
responsible for: 
1. Chemotaxis, 
2. Enhanced bronchial responsiveness, and/or 
3. Sensitization to vasoactive mediators.[7,25] 
 
Disorders of mast cell activation and/or proliferation 
Mast cells are best known for their role in immediate hypersensitivity reactions like anaphylaxis 
as well as allergic disorders such as asthma and urticaria. They are also suspected to be involved 
in other chronic inflammatory disorders such as multiple sclerosis. Diseases arising from 
abnormal and excessive mast cell production are generally referred to as mastocytosis. 
 
Systemic mastocytosis 
Systemic mastocytosis describes a group of disorders that result from the abnormal 
accumulation of mast cells and their precursors in various tissues.[28-30] Mastocytosis occurs in 
all age groups and is frequently linked to a mutation in the receptor for stem cell factor  (KIT).[10] 
Symptoms may include headaches, dizziness, flushing, urticaria, hypotension, diarrhoea and 
abdominal pain.[30,31] The symptoms of mastocytosis arise due to: 
1. Uncontrolled mast cell production, 
2. Infiltration and accumulation of mast cells within organs (i.e. bone marrow, skin liver, spleen 
and lymph nodes),[10] and/or 
3. Release of mast cell mediators.[30] 
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The World Health Organization divides mastocytosis into three main categories, these being: 
1. Cutaneous mastocytosis  (only skin involvement), 
2. Systemic mastocytosis (extra-cutaneous involvement) with multiple sub-types, i.e. indolent, 
aggressive, non-mast cell clonal haematological disease, and 
3. Mast cell neoplasms such as mast cell leukaemia. [28,29] 
 
 
The diagnostic criteria for systemic mastocytosis are listed in Table 1. To establish the diagnosis, 
either a major criterion together with one minor criterion or all three minor criteria should be 
present.[28]  
Table 1. 
Diagnostic WHO criteria for systemic mastocytosis (SM) criteria 
Major Criteria 
Multifocal compact infiltrates of mast cells in bone marrow or other extra-cutaneous 
organ(s). (more than 15 mast cells) 
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Minor Criteria 
a. Mast cells in bone marrow or other extra-cutaneous organ(s) show an abnormal 
spindle shaped deformity (>25%) 
b. C-kit mutation D816V in extra-cutaneous organ(s) 
c. Serum tryptase >20ng/ml (does not count in patients who have an associated 
haemopoietic clonal non mast cell lineage disease. (=AHMND) 
d. Mast cells in the bone marrow express CD 2 and/or CD 25 
If at least one major and one minor criterion or three minor criteria are fulfilled, the diagnosis 
of systemic mastocytosis can be established. 
 1 other activating mutations at codon 816 of c-kit also count as a minor criterion 
 
 
Mast cell tryptase (total tryptase levels) are used both to diagnose systemic mastocytosis and 
also to monitor the response to treatment. Total tryptase levels reflect the ‘mast cell burden’ as 
mast cells continuously secrete immature pro-alpha tryptase, thus tryptase levels parallel the 
number of mast cells present, the so called ‘mast cell burden’.[30] 
 Monoclonal mast cell activation syndrome (MMAS) 
Patients with monoclonal mast cell activation syndrome have symptoms suggestive of mast cell 
activation (periodic hypotension, flushing, urticaria etc.) but do not meet the diagnostic criteria 
for systemic mastocytosis.[32] 
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Anaphylaxis 
The National Institute of Allergy and Infectious Diseases/ Food Allergy and Anaphylaxis Network 
Symposium define anaphylaxis as a “serious allergic reaction that is rapid in onset and may 
cause death”.[33-36] Estimated lifetime prevalence has been quoted to be between 0.05 to 2% 
with an incidence under anaesthesia thought to range between 1 in 10 000 to 1 in 20 000 
procedures.[24,27,33,34,37-42] The occurrence of anaphylaxis during anaesthesia seems to be 
increasing.[24,43] 
 
The pathophysiology of anaphylaxis involves the activation of mast cells and basophils, which 
can occur through both immune and non-immune mechanisms.[24] Immune-mediated or so-
called “allergic anaphylaxis” is most commonly initiated by immunoglobulin E binding to its high 
affinity receptor on mast cells and basophils.[43] Other non-IgE dependent immune pathways 
include complement activation through immunoglobulin M, immunoglobulin G, and immune 
complexes. 
 
 
Non-Immune mediated anaphylaxis occurs through direct activation of mast cells and 
basophils.[39,43,44] Triggers for direct mast cell degranulation may include: 
1. Drugs such as morphine, possible mechanisms are discussed later, 
2. Toxins and chemicals[5] as well as 
3. Contrast media and radiation.[38,44,45] 
Clinical signs of Anaphylaxis usually start appearing anywhere between five to thirty minutes 
after contact with an allergen, although it can sometimes be delayed by several hours. Biphasic 
reactions occur in up to 20% of patients without being re-exposed to the agent. It normally 
occurs in the first eight hours but has been reported to occur as late as 72 hours after the initial 
event.[37] Immune-mediated anaphylactic reactions tend to become more severe when the 
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patient is re-exposed to the same agent. This is unlike non-allergic reactions, which are usually 
more dependent on the total amount of antigen given.[43] The main organ systems involved in 
order of frequency are: skin/mucosal, respiratory, gastrointestinal, cardiovascular and 
neurological.[24,38] Clinical features of anaphylaxis can range from mild, localized skin signs to 
life-threatening multi-organ failure.[33] Life-threatening features may include laryngeal 
oedema resulting in upper airway obstruction, severe bronchospasm, and anaphylactic shock 
with tachycardia, hypotension, bradycardia and ultimately cardiac arrest.[33,34,37,38] 
 
Anaphylaxis is a clinical diagnosis.[27,37] Contact with a known trigger, time to the start of 
symptoms and progression of signs to involve more than one organ system is very 
suggestive.[24] Clinical diagnosis is difficult in patients undergoing anaesthesia as patients are 
covered by surgical drapes, have multiple drug administrations and access to the patient is 
limited.[46,47] Markers of massive mast cell degranulation such as mast cell tryptase and 
plasma histamine can be valuable in supporting the diagnosis of anaphylaxis. 
 
Markers of mast cell activation 
 
The most commonly performed laboratory investigations to confirm mast cell activation are 
plasma histamine and tryptase levels. As both mature beta tryptase and histamine is stored in 
mast cell organelles and are released during mast cell degranulation, raised levels detected 
systemically thus point toward mast cell activation.[24] Neither plasma histamine levels nor 
total tryptase levels are currently optimally sensitive or specific for the diagnosis of 
anaphylaxis.[24,27]  
 
Histamine and histamine metabolites may be used as markers of mast cell activation. Histamine 
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is stored in both mast cells and basophils.[36] It is broken down rapidly by the enzyme histamine 
methyl transferase, which is present in most tissues.[11,25] Due to its rapid breakdown 
histamine has a short half-life [48]; this means that plasma histamine levels normally peak early 
at approximately 5-10 minutes and disappear within 30-60 minutes.[11,37,38]  Obtaining 
histamine levels after anaphylaxis is difficult as levels need to be taken within one hour after the 
start of symptoms (during which time resuscitation is taking place).[27,37] Furthermore, 
specimens require special handling, and should be: 
1. Taken using a wide bore needle, 
2. Cooled by placing on ice and then 
3. Centrifuged and plasma frozen immediately.[24] 
 
An alternative not commonly used in anaesthesia is to measure histamine metabolites in 24-
hour urinary samples.[27] 
 
Mast cell tryptase is the most frequently used laboratory test in anaphylaxis as it is considered 
to be more specific than histamine.[29,30,49,50] Tryptase is found mostly in mast cells, with 
only trace amounts stored in circulating basophils (basophils contain roughly 0.002% of the 
tryptase that is present in mast cells)[48] Because tryptase is essentially exclusive to mast cells, 
elevated levels in serum are used as an indicator of mast cell activation.[5,51,52] Resting mast 
cells normally secrete immature pro-beta and pro-alpha tryptases, (predominantly pro-beta 
tryptases) creating a baseline blood level.[26,48,51,53-55] This resting serum level is regarded 
as an indication of mast cell ‘load’, being elevated in conditions like mastocytosis, where 
excessive amounts of mast cells accumulate in tissues.[26] Mast cell granules store just the 
mature form of beta tryptase, which is released via exocytosis only after mast cell activation. 
Mature beta tryptase thus denotes mast cell degranulation and should not normally be present 
in serum.[26] 
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Beta tryptase within the mast cell granules bind to proteoglycan groups (like heparin), forming 
large stable compounds.[5] The large size of the tryptase-proteoglycan complex means that 
after its release diffusion is slow, explaining the later appearance of tryptase in the circulation as 
compared to histamine whose levels peak early, despite the fact that they are secreted at the 
same time[26,48] Based on research conducted by Schwartz et al., beta tryptase levels reached 
maximum values at approximately 1-2 hours after wasp sting venom induced anaphylaxis 
(Figure 1).  The half-life of beta tryptase was found to be between 1.5 hours and 2 hours.[26] 
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Figure 1. 
 
The hypothetic time course for the appearance of mature beta tryptase in serum or plasma during 
systemic anaphylaxis. The maximum level is set at 100% in the figure, however in reality, it varies 
at least in part depending on the severity and nature of the anaphylactic stimulus, which in turn 
affects how long mature tryptase is in the detectable range. 
 
The longer half-life of mature beta tryptase means that serum levels should ideally be taken 
within 2 hours after the anaphylactic episode. Serum levels will also stay raised for up to 6 hours, 
only returning to normal resting levels after 14 hours.[26,48] After a suspected anaphylactic 
episode it is recommended that a blood sample should be taken an hour after the start of the 
allergic reaction to determine peak tryptase levels and again after 24 hours to document 
baseline tryptase levels.[56] There appears to be an association between the severity of the 
allergic reaction and the peak tryptase levels in some studies.[52] Normal baseline levels of total 
tryptase lie between 1 to 15 mcg/L, although other, lower reference values exist.[26] The 
accurateness of mast cell tryptase levels in diagnosing serious allergic reactions can also be 
improved by: 
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1.  Preforming multiple measurements (determining at least a peak and baseline value), 
2.  Measuring plasma histamine levels simultaneously, and/or 
3.  Measuring both mature beta tryptase and total tryptase levels.[56]  A ratio of total to mature 
beta tryptase of 10 or below is indicative of anaphylaxis.[26,57]  
An increase in total tryptase levels of 20% or more from the baseline is suggestive of mast 
cell activation.[49,58] 
 
Tryptase levels are much more likely to be raised when anaphylaxis is triggered by a parentally 
administered allergen, when the reaction is immunologically mediated and when the reaction is 
severe and hypotension results.[24] This is probably due to delivery of large amounts of allergen 
directly to mast cells resulting in rapid and extensive mast cell degranulation.[26]   
 
Patients with elevated baseline levels of tryptase can have false-positive results when measuring 
only peak tryptase levels to investigate anaphylaxis. Elevated baseline total tryptase levels may 
occur in patients with: 
1. Mast cell disorders like mastocytosis, 
2. Other myelodysplastic and myeloproliferative disorders, 
3. Acute or chronic myeloid leukemia, 
4. Hypereosinophillic syndrome, 
5. Allergic or atopic disorders, 
6. Trauma, 
7. Myocardial infarction,      
8. Heroin use, 
9. Hypoxia, and/or 
10. End-stage kidney disease.[5,10,26,58] 
False-positive tests have also been described in post-mortem samples in patients whom had 
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coronary artery disease, salicylate poisoning and whom suffered multiple trauma.[26,48,53-
55,59] In some cases of anaphylaxis, tryptase levels may not become notably elevated, meaning 
that the diagnosis of anaphylaxis cannot be excluded by a negative result.[35,36,58,60] False-
negative results may be attributed to: 
1. Localized mast cell activation, the extent of which is not great enough to increase systemic 
serum tryptase levels,[5] or 
2. Anaphylaxis possibly mediated through basophils, which contain only minute quantities of 
tryptase as compared to mast cells,[5] or 
3. Food-induced anaphylaxis. This may be as a result of: 
3.1. Smaller peak tryptase levels occurring later in the course of the reaction due to the more 
gradual onset of food induced anaphylaxis, 
3.2. Local activation of mucosal mast cells confined to the gut, which in turn also contain less 
tryptase when compared to cutaneous mast cells, and 
3.3. Loss of tryptase into the gut lumen resulting in lower concentrations reaching the 
systemic circulation.[51] 
 
Opioids and mast cell activation 
 
True type-one hypersensitivity reactions to opioids are very rare,[36] being implicated in only 
one percent of all assumed perioperative anaphylactic events.[61] Many of the frequently used 
opioids such as morphine, pethidine and codeine are histamine releasers.[61,62] The 
importance of this is that these drugs are capable of producing signs and symptoms that imitate 
true anaphylactic reactions. However, in contrast to true anaphylactic reactions these 
symptoms might not return or may be less severe if the agent is administered more slowly or at 
a lower dose.[43] Opioids in general differ in their ability to provoke mediator release from mast 
cells, and different mast cell populations are not equally responsive to opioids.[63,64] 
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Fentanyl is a potent synthetic opioid that is popular in the perioperative period due to its rapid 
onset and short duration of action. Even though fentanyl is roughly ten times as potent as 
morphine it results in little or no histamine release, as it is unable to activate mast cells. Skin 
reactions have been credited to direct dilatory actions on capillaries.[61] 
 
Morphine is an opioid analgesic drug that exerts most of its effects through activation of Mu-
receptors. When given rapidly or in large doses, histamine release is a frequent side effect, 
resulting in undesired hemodynamic changes, particularly hypotension and increased cardiac 
output.[65] Hypotension after the administration of large doses of morphine appears to be 
mediated by both the direct vasodilating actions on veins by a yet unknown mechanism  and 
because histamine release results in venous and arteriolar dilatation decreasing systemic 
vascular resistance.[61] 
 
In-vitro studies by Stellato et al. and Veien et al. showed that mast cell tryptase is released along 
with histamine from isolated human skin mast cells after morphine administration.[63,66] 
Furthermore, morphine was shown to produce dose-dependent release of mast cell mediators’ 
tryptase and histamine from cutaneous mast cells in-vitro, without stimulating the production 
of prostaglandins.[63,65] Morphine appears to degranulate skin mast cells directly and non-
immunologically[66] liberating histamine[36] and mast cell mediators independently of opioid 
receptors or opioid-specific IgE.[61,62] The precise mechanism is still uncertain. Currently, in-
vivo studies evaluating the effects of large intravenous doses of morphine on systemic tryptase 
levels are lacking. An in-vivo study by Blunk et al. using intra-dermal microdialysis demonstrated 
morphine’s ability to activate skin mast cells with the subsequent release of histamine and 
tryptase.[62] They speculated that the mechanism could be through concentration-dependent, 
direct activation of mast cell G proteins. Rook et al. investigated the effects of high dose 
pharmaceutically prepared heroin on mast cell tryptase levels in patients who were chronically 
treated with both heroin and methadone for heroin addiction. He concluded that following 
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intravenous heroin injection plasma tryptase levels increased dose-dependently (average 
increase was 23%). Interestingly, the percentage change in tryptase levels related to the peak 
morphine concentrations and not heroin concentrations.[67] A study by Fisher et al. 
investigated systemic mast cell tryptase levels in 350 patients with suspected anaphylactic 
reactions whilst undergoing anaesthesia.  They concluded that mast cell tryptase is a very 
sensitive and useful indicator of anaphylactic reactions, although it cannot distinguish between 
an IgE and non-IgE mediated process.[68-71] A prospective study by van der Linden et al. 
investigated the relationship between the severity of insect sting induced anaphylaxis and 
plasma levels of mast cell mediators. They demonstrated that mast cells are activated during 
insect-sting anaphylaxis and that the severity of the subsequent anaphylactic episode correlated 
with the circulating levels of both histamine and mast cell tryptase, but not with the levels of 
prostaglandin (PGD2).[72] 
 
The rationale for using morphine rather than fentanyl during cardiac surgery is much debated. 
Fentanyl is a popular opioid choice in cardiac surgery due to its potency and cardiovascular 
stability.  Fentanyl, unlike morphine, does not activate mast cells to release histamine, thus 
avoiding hypotension, which may follow after rapid or large dose morphine administration. 
However, morphine’s cardioprotective, anti-inflammatory and advantageous post-operative 
analgesic profile makes it a favourable choice for use in patients during cardiac surgery and 
cardiopulmonary bypass. 
 
The cardioprotective properties of morphine have been shown in in-vitro animal studies. Liang 
et al. demonstrated that the activation of functional opioid receptors on myocytes “mimics the 
cardioprotective effect of ischaemic preconditioning”.[73] This effect was dose-dependent and 
blocked by naloxone. The precise mechanism of morphine’s preconditioning effect on myocytes 
remains uncertain. Animal data suggests that it occurs through activation of the delta1 opioid 
receptor. This direct receptor activation is thought to result in activation of mitochondrial 
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potassium ATP channels with a resultant increases in intracellular free radicals.[73] 
 
Morphine possesses beneficial anti-inflammatory and immune-regulatory properties. Patients 
undergoing coronary artery bypass graft surgery and cardiopulmonary bypass who received 
morphine rather than fentanyl demonstrated reduced levels of pro-inflammatory cytokines as 
well as reduced expression of neutrophil adhesion molecules.[74,75] Fentanyl, on the other 
hand, does not appear to have the same immune regulating properties exhibited by 
morphine.[76] 
 
Patients who had received morphine rather than fentanyl during elective cardiac surgery and 
cardiopulmonary bypass experienced less early post-operative pain, had significantly better 
subjective quality of recovery scores as well as less febrile episodes during the first three post-
operative days.[75]  
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The study in article format 
 
Title: The effect of high dose morphine compared to fentanyl infusion on serum 
levels of mast cell tryptase during cardiac surgery  
Short title: Mast cell tryptase following high dose morphine 
Abstract 
Background: Morphine directly activates cutaneous mast cells in a seemingly dose-dependent 
manner, resulting in the release of both histamine and tryptase into the bloodstream. Tryptase 
is almost exclusively stored in mast cells. Elevated serum tryptase concentrations serve as an 
indicator of mast cell activation and have become the most frequently used laboratory 
investigation in anaphylaxis. Following a clinical diagnostic dilemma our study was aimed at 
answering whether mast cell tryptase concentration remains useful in supporting the diagnosis 
of anaphylaxis even after administration of high dose morphine.  
Methods:  We conducted a non-blinded, randomized controlled trial comparing the effects of 
fentanyl and high dose morphine, on serum mast cell tryptase concentrations. A power analysis 
was performed. Twenty adults undergoing cardiac surgery were randomly assigned to one of 
two opioid regimens. Both groups received a fentanyl bolus of 3 to 8 mcg/kg at induction. In the 
fentanyl group this was followed by a fentanyl infusion of 5 to 10 mcg/kg/hr until completion of 
surgery. Patients in the morphine group received morphine 1 mg/kg infused over thirty minutes. 
Baseline serum mast cell tryptase concentrations were determined directly prior to induction of 
anaesthesia and again 90 minutes after the start of the opioid infusion. The primary endpoint 
was statistical differences in tryptase concentrations between the morphine and fentanyl 
groups at the two time periods.  
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Results: Ten patients of similar demographics were enrolled in each group. In the fentanyl group 
the second, 90-minute mast cell tryptase concentration was statistically significantly (10.1%) 
lower (p = 0.006) than baseline. Despite the 95% confidence interval of the difference between 
the means (-1.06  to -0.34 mcg/L) not including zero , this was not a clinically important 
difference. 
In the morphine group serum mast cell tryptase concentrations in the second (90 minute) 
sample were not statistically different from baseline values, the 95% confidence interval 
including zero. No between-group differences in tryptase concentration, were detected.  One 
patient in the morphine group exhibited a clinically significant 50,4% increase in tryptase 
concentrations, albeit from a high baseline of 11.9 mcg/L, which in this small study constitutes a 
prevalence of 10% (95% CI 1.8% to 40.4.) 
Conclusion: In this small pilot study, serum mast cell tryptase concentrations were unaffected 
by whether fentanyl or high dose morphine was administered. The null hypothesis, that there is 
no significant increase in serum mast cell concentrations after high dose morphine compared to 
fentanyl during cardiac anaesthesia and surgery, was therefore accepted. Larger studies are 
however needed to ensure a robust result, especially in the morphine group. 
 
Keywords 
Mast cell tryptase 
High dose morphine 
Anaphylaxis 
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Background and rationale 
  
At the end of an otherwise uneventful hip arthroplasty conducted under spinal anaesthesia, a 
patient known with single vessel coronary artery disease suffered a cardiac arrest. Spontaneous 
circulation was restored after only 3 CPR cycles. An attending anaesthesiologist suggested 
administration of a large 1 mg/kg dose of morphine would facilitate overnight sedation and 
ventilation. This was administered over approximately 40 minutes. Towards the end of the 
morphine infusion, urticaria were noted on the patient’s legs. Serum tryptase (34mcg/L) was 
significantly elevated. While anaphylaxis was suspected as a cause for the cardiac arrest, the 
question arose whether the morphine, particularly in such a high dose, could explain the 
increased tryptase levels. Despite conclusive evidence of histamine release following morphine 
administration,[61,65] we could not identify human research indicating the effects of high dose 
morphine on tryptase concentrations. 
 
As high dose morphine is commonly used in cardiac surgery our institution, we elected to 
investigate tryptase levels after high dose morphine.   
 
Methods 
 
Hypotheses 
The null hypothesis was that there is no significant increase in serum mast cell tryptase levels 
after high dose morphine administration in humans undergoing cardiac surgery. The alternative 
hypothesis was that serum mast cell tryptase levels rise significantly to levels seen during 
anaphylaxis after administration of high dose morphine in humans undergoing cardiac surgery. 
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Primary endpoints of the study 
The primary endpoint was statistical and clinical (20% increase from baseline) differences in 
tryptase levels between the groups M and F at the two time periods.[31,58] 
 
Ethics and consent 
Ethics approval was obtained before commencement of the study (Addendum A). Informed 
consent was obtained before enrolment into the study.  
 
Inclusion criteria 
Inclusion criteria comprised the following: 
1. Patients scheduled for elective or emergent cardiac surgery, 
2. Patients with both good or poor left or right ventricular function, 
3. Patients receiving aspirin and/or heparin preoperatively, 
4. Patients scheduled for valve and coronary artery bypass grafting, or both, 
5. Patients scheduled for either on or off pump coronary artery bypass grafting, 
6. Patients with a definitive history of allergy to penicillin, although cephalosporin will also be 
avoided in these patients, and/or 
7. Patients with an intra-aortic balloon pump already in situ. 
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Exclusion criteria 
Exclusion criteria comprised the following: 
1. Patients scheduled to undergo non-cardiac surgery, 
2. Previous history of allergy to anaesthesia agents or drugs commonly used during 
anaesthesia and surgery, including muscle relaxants and/or opioids, particularly morphine, 
latex or “Elastoplast”®, 
3. Patients with a diagnosis of asthma, 
4. Patients with current bronchospasm from any cause, such as pulmonary oedema, 
5. Patients receiving steroids, antihistamines or chromoglycate, both pre- or intra-operatively, 
6. Patients who had any form of unregulated mast cell proliferation such as urticaria 
pigmentosa, systemic mastocytosis, or any concurrent haematological malignancy, 
7. Patients with current or previous diagnoses of pheochromocytoma, paraganglioma, or 
carcinoid tumours, 
8. Patients known with or suspected to have malignant hyperpyrexia, 
9. Patients having received morphine for any reason except premedication in the previous 24 
hours, 
10. Patients with severe hypotension preoperatively, defined as a mean blood pressure of 60 
mm Hg or less, 
11. Monoclonal Mast Cell Activation Syndrome, 
12. Patients where postoperative, overnight ventilation was not intended, 
13. Patients for thoracotomy for lung surgery, 
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14. Patients with known hypothyroidism, 
15. Patients with known hepatic disease severe enough to cause abnormality in bilirubin, 
albumin concentration or abnormal international normalized ratio. 
16. Patients with renal insufficiency such that they are on dialysis or have an estimated 
glomerular filtration rate less than 50 ml/minute, and/or 
17. Patient with a body mass index of more than 35 or less than 18 kg/m2. 
 
Sample size and randomization 
We could identify no studies on which to base a power analysis.  We therefore assumed that 
mean serum tryptase concentrations of 2 and 8 mcg/L with standard deviations of 2 and 8 mcg/L 
respectively could be expected in the control and morphine groups.  Inputting these 
assumptions into Sigmastat® for Windows® version 2.03 indicated that studying 10 patients in 
each group would achieve a 80% chance of identifying a difference between groups with a 5% 
alpha error.  
 
Randomization was attained by blind drawing of an envelope by the anaesthesiologist 
containing the data sheet and group selection. 
 
Anaesthesia premedication  
Premedication comprised diazepam 5 to 10 mg administered orally two hours before arrival in 
the induction room. Premedication explicitly excluded morphine or promethazine. 
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Conduct of anaesthesia 
Except for the opioid administration, conduct of anaesthesia was left to the discretion of the 
attending anaesthesiologists. It was important that the conduct followed the routine, standard 
conduct of anaesthesia and surgery in our institution so that the results of the study are clinically 
applicable. The choice of drugs for maintenance and induction of anaesthesia was determined 
by the attending anaesthesiologist.  
 
A fentanyl bolus of 3 to 8 mcg/kg, was used during induction of anaesthesia.    
 
Vecuronium 0.15 mg/kg or rocuronium 1 mg/kg was administered to facilitate tracheal 
intubation. 
 
After induction and tracheal intubation, the patients were randomized into one of two groups: 
1. Group M: morphine 1 mg/kg lean body weight was administered after induction of 
anesthesia and completion of tracheal intubation. The total dose morphine was diluted to 
50 millilitres in a syringe with normal saline and administered over 30 minutes. This practice 
was commonly performed in approximately one third of cases in our institution. This served 
as the intervention group. 
2. Group F: Fentanyl group: administration of fentanyl as an infusion at 5 to 10 mcg per kg per 
hour until the completion of anaesthesia. This served as the control group. 
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Blood sampling and processing 
Five millilitre blood samples were obtained from the intra-arterial cannula at the following 
times:  
1. Before induction of anaesthesia, after the placement of the intra-arterial catheter but prior 
to administration of antibiotics. 
2. Sixty minutes after completion of the morphine infusion.  This was to be before starting 
cannulation for initiation of cardiopulmonary bypass. 
 
Samples were processed in a particular way. Blood samples were stored in 5ml EDTA gel tubes. 
These specimens were stored at 2 to 8 degrees centigrade in our hospital. Within 3 days, 
specimens were transferred to the UCT Lung Institute in Mowbray, Cape Town, South Africa. At 
the Lung Institute, samples were spun down at 4000 revolutions per minute; the serum was 
decanted and then frozen at -20 degrees Celsius. Once a sufficient number of samples were 
available, a batch analysis for tryptase was performed, a more cost effective method. 40 samples 
were tested at a price of R192 each, compared to R900 normally charged for a single sample at 
the National Health Laboratory Service in Cape Town, South Africa. 
 
Total serum tryptase levels were measured using the ImmunoCAP® method (Thermo Fisher 
Scientific Inc., Phadia AB, Uppsala, Sweden). Three monthly external tryptase quality controls, 
specific to this method, were performed. A particular trained technician, Ms. Bartha Fenemore, 
was responsible for all tryptase analyses.  
 
We derived serum tryptase reference values from a study in 126 healthy persons aged between 
12 to 61 years indicated a geometric mean of 3,8 mcg/L and an upper 95th percentile of 11,4 
mcg/L.  This study is reported in the package insert and website of the only commercially 
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available test for measuring Tryptase concentrations, the ImmunoCAP® method. However, it is 
not clear whether this data has been peer reviewed and/or published as a paper. 
 
The data was inputted into an Excel® spread sheet and all data points were checked before 
analysis.   
Results  
 
Medcalc® version 15 was used to perform statistical analysis. Data was tested for normality of 
distribution (Kolmogorov Smirnov test; p < 0.05) and equality of variance (Levene Median test; 
p < 0.05). The Kolmogorov-Smirnov test revealed that all data was normally distributed. 
Normally distributed, parametric data, which exhibited equal variance, was analysed with the 
appropriate t-test. The one instance of between-group data (second sample) with unequal 
variances was analysed using nonparametric (Man Whitney) tests. The strength of association 
for data that was both normally distributed and also exhibited a constant variance was measured 
using the Pearson product moment correlation.  Otherwise, Spearman rank order correlation 
was be used to measure the strength of associations. 
 Ten patients per group were enrolled in the study. There was no missing data. Demographics 
(age, gender, height, weight and surgical procedure (Table 2) did not differ between groups. 
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Table 2. 
 Fentanyl	 	 	 Morphine	 	 	 p	 95%	CI	of	
difference	
between	means	
test	used	
	 Mean	 Standard	
Deviation	
95%	
Confidence	
intervals	
Mean	 Standard	
deviation	
95%	
confidence	
interval	
	 	 	
Age	 60	 8.4	 53 -67 57 14.6	 44-70	 0.6444	 -13,69	to	8,69	 unpaired	T-test	
Weight	 77	 20	 59- 87 71 13	 60-80	 0.4225	 -21,89	to	9,59	 unpaired	T-test	
Height	 151	 53	 156-174 169 13	 160-178	 0.937	 -0.10	to	0.10	 unpaired	T-test	
Gender	 Female=1	
	
Male=0	
	  Female=3 
 
Male=7 
	 	 0,513	 	 Chi-squared	
ASA		 ASA	2=2	
	
ASA	3	=8	
	
	
	 ASA	2	=	3	
	
	ASA	3	=	7	
	 	 1	 	 Chi-squared	
Surgery	 CABG	x10	 	 	 CABG	x	10	 	 	 0,823	 	 Chi-squared	
Allergy	
history	
None	 	 	 One	
penicillin		
	 	 1	 	 Chi-squared	
 
Study participants demographic data 
 
Results are presented in Table 3 and 4 as means and standard deviation, and as medians and 
interquartile ranges, respectively. The 95% confidence intervals are presented for both means 
and medians. The 95% confidence intervals for non-parametric data were determined using 
Confidence Interval Analysis® Software, version 2.2.0 (BMJ Books, London, UK).  
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Table 3. 
 
Data presented as medians and 95% confidence intervals of the median. Concentrations measured 
in mcg/L. 
 
Table 4. 
 
 Data presented as means ± standard deviation and 95% confidence intervals of the mean. 
Concentrations reported in mcg/L. 
 
Opioid Tryptase 
concentration 
sample 1  
95% 
confidence 
interval for 
the  median 
Tryptase 
concentration 
sample 2 
 
95% 
confidence 
interval for 
the median 
P 
 (Wilcoxon 
signed 
ranks) 
95% 
confidence 
interval of 
Difference 
Fentanyl 5.40 4.08 to 6.99 4.85 3.33 to 6.14 0.006 -1.06 to -0.34 
Morphine 4.92 3.25 to 9.67 4.47 3.33 to 10.02 0.56 -0.79 to 2.29 
Opioid Tryptase 
concentration 
sample 1 
 Mean 
±Standard	
deviation 
95% CI 
mean 
Tryptase 
concentration 
sample 2 
95% 
confidence 
interval for 
the mean 
Two tailed 
probability 
95% confidence 
interval of 
difference 
Fentanyl 5.6 4.2 to 
7.0 
4.9 3.7 to 6.1 P= 0.002 -1.1 to -0.3 
Morphine 6.1 3.3-9.0 6.3 2.6-10.0 P= 0.7 -1.3-1.76 
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In the fentanyl group, baseline tryptase concentrations were all within the reference range. The 
second, 90-minute tryptase concentration was (10.1%) statistically significantly lower than 
baseline, the 95% confidence interval of the difference between the means not including zero. 
The low p-values indicated only a small chance of incorrectly making such a conclusion. This 
decrease in tryptase concentration was not clinically significant (fig 2).  
 
In the morphine group, baseline tryptase concentrations were within the reference range. 
Serum tryptase concentrations in the second (90 minute) sample were not statistically different 
from baseline values, the 95% confidence interval including zero. No clinical difference between 
the initial and follow-up tryptase concentrations was observed (fig 2).  
 
No between-group differences in tryptase concentration were detected.   
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Figure 2. 
 
Graph of median values with error bars displaying the 95% confidence intervals. 
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Discussion 
We conducted a non-blinded, randomized controlled trial comparing the effects of fentanyl, or 
fentanyl followed by high dose morphine, on total serum tryptase concentrations. Fentanyl 
administration alone resulted in a statistically significant, but clinically insignificant 10,1% 
decrease in total serum tryptase. (Fentanyl followed by) high dose morphine administration did 
not alter the follow up tryptase concentrations. In summary, total baseline tryptase was 
unaffected by either fentanyl or high dose morphine administration. The null hypothesis, that 
there is no significant increase in serum mast cell tryptase concentrations after high dose 
morphine compared to fentanyl during cardiac anaesthesia and surgery, was therefore 
accepted. 
 
Opioids and mast cell activation  
Mast cell activation is best known as the ultra-rapid degranulation as seen in anaphylaxis.[17,19] 
However, slower, selective secretion of granular content and/or selective chemokine synthesis 
alone can occur.[77] Morphine activates mast cells non-immunologically, independent of both 
opioid receptors and opioid-specific IgE,[16,61,62,66] without stimulating prostaglandin 
production.[64,65] Morphine possibly initiates mast cell degranulation via concentration-
dependent, direct activation of mast cell surface G proteins. 
 
Mast cells occur in many tissues, with mast cells populations in different locations varying with 
respect to their granular contents, susceptibility to activation, and post-activation biological 
responses.[2,21,78] This mast cell inhomogeneity is attributed to differences in mast cell surface 
receptors as well as downstream signalling pathways. The detailed biology of the 
inhomogeneity is not yet well understood.  Indeed, individual mast cell populations react 
differently to opioids. In-vitro studies by Stellato et al, Veien et al, and Blunk et al. demonstrated 
morphine predominantly activates the cutaneous mast cell population.[61,64,66] 
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Opioids vary as to their ability to activate mast cells. Authoritative anaesthesia and 
pharmacology textbooks state that intravenous administration of certain commonly used 
opioids, including morphine, pethidine, and/or codeine, initiate mast cell activation. [79,80] This 
is followed by increases in plasma histamine concentrations. The higher the opioid dose, the 
greater the extent of mast cell activation, histamine release and systemic hypotension. 
However, fentanyl and its derivatives do not activate mast cells or initiate histamine 
release.[61,62,64,65,79,81] In this light, it was surprising that high dose morphine did not result 
in a measurable increase in serum tryptase concentrations.  
 
No change in tryptase with morphine 
Mast cell tryptase concentrations did not differ statistically or clinically from baseline following 
morphine administration. In addition, no post- opioid administration, between-group tryptase 
concentration differences were observed.  As far as we can determine, this has been not been 
described before. This is an interesting finding as we expected that morphine would cause a 
dose-dependent rise in tryptase concentrations. Indeed, Rook et al. observed that the increase 
in plasma tryptase following intravenous heroin was related to the peak morphine 
concentrations and not heroin concentrations.[67]  
 
It is interesting to speculate why the expected rise in tryptase concentrations did not occur. As 
histamine concentrations increase after morphine administration,[61,64,82] we cannot 
conclude that mast cell degranulation with release of granular tryptase does not occur. 
Morphine selectively activates (cutaneous) mast cell populations and particular mast cell 
pathways.[64] It may be that the extent of cutaneous mast cell activation may not be sufficient 
to elevate systemic levels.  
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We also questioned whether we missed the peak rise in tryptase concentrations. The second 
sample, presumably indicating peak tryptase concentrations, was collected 90 minutes after 
commencement of the morphine infusion. The rationale for sampling at 90 minutes was that 
Schwartz et al observed peak beta tryptase levels to occur between 1 to 2 hours after wasp sting 
venom induced anaphylaxis.[48] Thus, taking the second sample at 90 minutes would 
presumably reflect post morphine, peak tryptase concentrations. It may be that this was not the 
correct model on which to base the effects of morphine. It may have been that the slow rate of 
morphine infusion with gradual mast cell activation resulted in a smaller peak tryptase 
concentration occurring later than 90 minutes after start of the infusion. Thereby sampling at 90 
minutes missed peak tryptase levels. On the other hand, the dose of morphine administered was 
large, and the period over which it was administered was relatively short. We would have 
expected a small rise in tryptase if it did occur. However, we could not delay tryptase sample 
collection any further as this would have been during initiation of, or even during, 
cardiopulmonary bypass. Nonetheless, should anaphylaxis be suspected and tryptase levels 
were raised, can conclude that this rise in tryptase was unlikely to be due to recent (within 60 to 
90 minute) large dose morphine administration. 
 
Administration of larger volumes of intravenous fluid in response to hypotension in the 
morphine group could have resulted in falsely low peak tryptase concentrations. We did not 
formally assess hypotension or other hemodynamic alterations during opioid administration. 
Furthermore, we did not investigate fluid administration between the first and second sample 
neither the fluid administration nor hypotension in either group. These are weakness of this 
study. We also did not document other clinical signs associated with mast cell degranulation 
such as evidence of bronchospasm, or skin manifestations. All these details will require 
recording in future, similar studies. 
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One patient exhibited a clinically significant increase in tryptase concentrations, which in this small 
study constitutes a prevalence of 10% (95% CI 1.8% to 40.4) (Figure 2). In this case, baseline and post 
morphine tryptase were 11,9 and 17,9 mcg/L respectively. This represents a baseline tryptase higher 
than what is regarded as normal and the 50.4 % rise is out of keeping with the other results in the 
morphine group. This patient could have had an underlying, undiagnosed mast cell disorder.   
 
The question is whether this single outlier invalidates the study conclusions? The absence of similar, 
previous research meant that we had to estimate values on which to base our power analysis. The 
results of our small pilot study did achieve a statistical and clinical significance. However, the outlier 
suggests more subjects need to be studied to ensure a robust result, particularly in the morphine group.  
The value of this study is that it provides valuable, hitherto unavailable data on which a larger study can 
be based. Using our data, a sample power calculation using a paired t-test (PASS sample size software, 
NCSS, LLC) concluded that a sample size of 667 would achieves 80% power to detect a difference of -
0.2 between the null hypotheses mean of 6.1 and the alternative hypothesis mean of 6.3 IU/ml with a 
known standard deviation of 2.1 and with a significance level (alpha) of 0.05.” Assuming a 5% to 15%, 
prevalence of tryptase exceeding 11.4 mcg/L, it would require a sample size of 134 in order to narrow 
down the 95% CI.  
 
Use of tryptase in diagnosis of anaphylaxis 
 
Tryptase is almost exclusive to mast cells, with serum mast cell tryptase concentrations being 
the most frequently used laboratory test in suspected anaphylaxis.[58] Elevated serum tryptase 
levels are an indicator of mast cell activation.[53] The clinical scenario we were confronted with 
was whether elevated tryptase levels were indeed due to allergy or if it could be attributed to 
morphine. Our study was aimed at answering whether mast cell tryptase levels remain useful in 
supporting the diagnosis of anaphylaxis after administration of high dose morphine. The ability 
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to confirm anaphylaxis will initiate the post-operative process of identification of the offending 
allergen and future avoidance of the probable allergens. 
 
Baseline serum tryptase concentrations result from secretion of “immature” pro-tryptases by 
resting mast cells, the 95% CI upper limit being less than 11.4 mcg/L.[26] Mast cell granules only 
store “mature” beta tryptase, which is released only after mast cell activation. Mature beta 
tryptase should not normally be present in serum. Its presence denoting mast cell 
degranulation.[26] Mature beta tryptase concentrations peak one hour after a serious allergic 
reaction, elevated for up to six hours, and achieve baseline levels only after 14 hours.[26] An 
increase in total tryptase levels of 20% or more from the baseline is suggestive of mast cell 
activation,[26,58] and a ratio of total to mature beta tryptase of 10 or below is indicative of 
anaphylaxis.[26] Tryptase concentrations are much more likely to be raised when anaphylaxis is 
triggered by a parentally administered allergen and when the reaction is severe (i.e. resulting in 
hypotension).[24] This is probably due to delivery of large amounts of allergen directly to mast 
cells resulting in rapid and extensive mast cell degranulation.[26] The current commercially 
available serum tryptase measurement methods available in South Africa indiscriminately 
measure both the immature and mature tryptase levels. 
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Rationale for using morphine during cardiac surgery. 
Morphine is even cheaper to acquire than fentanyl, a consideration in our cost-conscious 
environment. One risk is that injudicious use, particularly of excessive dosages of morphine may 
delay awakening and tracheal extubation, and be associated with additional costs.  
 
Fentanyl remains a popular opioid in cardiac surgery due to its potency and cardiovascular 
stability. Unlike morphine, fentanyl’s onset is relatively rapid. Fentanyl does not activate mast 
cells,[64,65] and is reported to produce less hypotension than morphine. [81,82] It is thus very 
suitable for use during induction of anaesthesia for cardiac surgery.  
 
Morphine mimics the cardioprotective effect of ischemic pre-conditioning.[73,74] Furthermore, 
morphine,[74,75] unlike fentanyl[76] possesses beneficial anti-inflammatory and immune-
regulatory properties. Morphine appears to lessen the inflammatory response after cardio-
pulmonary bypass through binding to the mu -3 morphine selective receptor, which fentanyl 
does not bind. A study by Murphy et al. showed significantly lower interleukin 6 levels after 
cardio-pulmonary bypass in patients receiving morphine rather than fentanyl during cardiac 
surgery.[74] 
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Patients who received morphine rather than fentanyl during elective cardiac surgery and 
cardiopulmonary bypass experienced less early post-operative pain, had significantly better 
subjective quality of recovery scores as well as less febrile episodes during the first three post-
operative days.[75]  
 
Remifentanyl is an ultra-fast-acting opioid often used during cardiac surgery. Its unique 
pharmacokinetic and pharmacodynamic profile allows for rapid onset of intense analgesia as 
well as fast and predictable recovery on cessation of the infusion. The concern with using 
remifentanyl is that hyperalgesia and opioid tolerance increases post-operative pain during 
major abdominal surgery.[83] These finding were confirmed in a recent systematic review and 
meta-analysis on randomized, controlled studies by Fletcher et al. They concluded that the use 
of high doses of remifentanyl intra-operatively significantly increased pain perception during 
the first 24 hours after surgery, with moderate increases in the amount of morphine required 
during that period.[84] Another serious concern with the use of remifentanyl during cardiac 
surgery is that it may be associated with chronic pain after sternotomy,[85] prospective studies 
are currently underway to investigate whether remifentanyl does indeed increase the incidence 
of chronic pain after cardiac surgery. 
 
The decrease in tryptase with fentanyl 
The decline of mast cell tryptase concentrations in the fentanyl group was an interesting, 
unexpected observation. The small 10.1% decrease was statistically significant with narrow 
confidence intervals confidence and low p-values. Despite being clinically unimportant, it is 
tempting to comment on this result. This finding has not been described before as far as we can 
determine. The fentanyl group decrease in serum mast cell tryptase concentrations may 
possibly be a result of haemodilution secondary to fluid loading, although this would rather be 
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expected in the morphine group. We cannot validate these speculations, as we did not quantify 
hypotension or assess fluid administration. The one convincing conclusion is that a rise in 
tryptase concentrations following fentanyl administration is not a physiologically expected 
result.  Unfortunately, the low numbers enrolled with low statistical power means that the 
statistically significant result in the fentanyl group is less likely to reflect a true difference. 
 
 
 
Summary and conclusions 
Mean serum tryptase concentrations did not increase 60 minutes after infusion of high dose, 1 
mg/kg, morphine administered over 30 minutes. The one outlier, with a baseline greater than 
normal and consequent 50.4% rise in tryptase levels, complicates the results. At the time of 
writing, we could identify no previous in-vivo studies evaluating the effects of large intravenous 
doses of morphine on systemic tryptase concentrations. In effect this is a pilot study. The value 
of the study is that it provides valuable, hitherto unavailable data on which a larger study can be 
based. A larger study will be needed to confirm the morphine group results. Fentanyl 
administration was followed by a 10.1% statistically significant, but clinically insignificant 
“decrease” in serum tryptase. This study indicates that a rise in serum tryptases unlikely to be 
due to fentanyl administration per-se. 
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